Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Tiragolumab in Combination With Atezolizumab and Bevacizumab in Patients With Previously Treated, Microsatellite Stable, Metastatic Colorectal Adenocarcinoma

NCT06784947 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT06784947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06784947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Tiragolumab in Combination With Atezolizumab and Bevacizumab in Patients With Previously Treated, Microsatellite Stable, Metastatic Colorectal Adenocarcinoma
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 25, 2025
Completion date
May 31, 2028
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer stage iv, metastatic colorectal cancer (crc), microsatellite stable (mss) colorectal cancer (crc)